期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

慢性粒细胞白血病对BCR-ABL酪氨酸激酶靶向抑制剂的耐药机制 被引量：5

Mechanism of drug resistance for chronic myeloid leukemia to BCR-ABL tyrosine kinase inhibitor
下载PDF
导出
摘要 BCR-ABL酪氨酸激酶抑制剂靶向治疗慢性粒细胞白血病(chronic myeloid leukemia,CML)能够达到良好的临床效应,然而随着其临床广泛应用,对其产生耐药逐渐增多。CML细胞多药耐药是目前导致化疗失败,缓解率降低,疾病复发的主要原因。本文就CML对BCR-ABL酪氨酸激酶靶向抑制剂耐药的主要机制进行了阐述。 Targeted therapy of chronic myeloid leukemia （CML） with BCR-ABL tyrosine kinase inhibitor shows a very good clinical therapeutic effect, but the drug resistance phenomena are increased with the wide use of tyrosine kinase inhibitor in clinic. Muhidrug resistance is the main reason of chemotherapy failure for CML patients accompanied by the decrease in remission rate and the increase in relapse rate. This review focus on the recent progress in the drug resistant mechanism for BCR-ABL tyrosine kinase inhibitor.
作者 肖宇航 秦群
机构地区 中南大学湘雅医院药剂科 中南大学药学院
出处 《国际病理科学与临床杂志》 CAS 2009年第6期524-528,共5页 Journal of International Pathology and Clinical Medicine
关键词 慢性粒细胞白血病 BCR—ABL酪氨酸激酶抑制剂 多药耐药 chronic myeloid leukemia BCR-ABL tyrosine kinase inhibitor multidrug resistance
分类号 R733.72 [医药卫生—肿瘤]
  • 相关文献

参考文献43

  • 1O'Brien SG, Guilhot F, Larson RA, et al. IRIS Investigators. lmatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia [J]. New Engl J Med,2003,348( 11 ) : 994-1004.
  • 2Gambacorti-Passerini CB, Gunby RH, Piazza R, et al. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosomepositive leukaemias[J]. Lancet Oncol,2003,4(2) :75-85.
  • 3Mahon FX, Hayette S, Lagarde V,et al. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression [ J ]. Cancer Res,2008,68 (23) :9809-9816.
  • 4Morinaga K, Yamauchi T, Kimura S, et al. Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification [ J ]. Int J Cancer,2008, 122( 11 ) :262! -2627.
  • 5Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation of amplification [ J ]. Science, 2001 , 293 (5531 ) :876-880.
  • 6Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib ( STI571 ) therapy[ J]. Leukemia ,2002,16( 11 ) :2190-2196.
  • 7Soverini S, Martinelll G, Rosti G, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival : a study by the GIMEMA Working Party on Chronic Myeloid Leukemia[ J]. J Clin Oncol,2005,23 ( 18 ) : 4100-4109.
  • 8Kim SH, Kim D, Kim DW,et al. Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T3151 mutation is disease phase dependent[J]. Hematol Oncol, 2009, 27(4):190-197.
  • 9O'Hare T, Eide CA, Deininger MW. New Bcr-Abl inhibitors in chronic myeloid leukemia : keeping resistance in check [ J ]. Expert Opin lnvestig Drugs, 2008,17 (6) : 865-878.
  • 10Liu J, Joha S, Idziorek T, et al. BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism[ J]. Leukemia, 2008,22 ( 4 ) :791-799.

同被引文献52

引证文献5

二级引证文献25

国际病理科学与临床杂志
2009年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部